TheraRadar
← Back
Data updated: Sep 20, 2026

NOVAX

Generics

NOVAX is a generic drug manufacturer focused on Neurology, Immunology, Respiratory.

2009
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

NOVAX's Key Drugs

NOVAX's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

NOVAX's Recent FDA Approvals

New NDA/BLA approvals for NOVAX over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

NOVAX's Therapeutic Areas

NOVAX's approved drugs and pipeline span 4 therapeutic areas, led by Neurology and Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 25%
1 drugs
Immunology 25%
1 drugs
Respiratory 25%
1 drugs
Gastroenterology 25%
1 drugs

NOVAX's Top Competitors

NOVAX's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

NOVAX Pipeline Snapshot

Active clinical trials for NOVAX across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling